Brought to you by 
GeneCentric licenses key diagnostic technologies from UNC Chapel Hill; later licenses additional IP
26 Sep 2018
Executive Summary
Molecular diagnostics start-up GeneCentric Diagnostics Inc. has licensed from the University of North Carolina at Chapel Hill exclusive rights to two technologies that will become the backbone for the company’s work in cancer diagnostics development.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GeneCentric licenses key diagnostic technologies from UNC Chapel Hill; later licenses additional IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice